Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga
Pier Paolo
PP
Institute of Haematology and Medical Oncology L. and A. Seràgnoli, S. Orsola-Malpighi Hospital, University of Bologna, Italy.
Martinelli
Giovanni
G
Rondoni
Michela
M
Malagola
Michele
M
Ronconi
Sonia
S
Visani
Giuseppe
G
Baccarani
Michele
M
D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D000079982:Gemtuzumab; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D000922:Immunotoxins / Q000008:administration & dosage / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D003561:Cytarabine; D005047:Etoposide; D000079982:Gemtuzumab; D015255:Idarubicin